Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
09.11. | TELA Bio Inc reports results for the quarter ended September 30 - Earnings Summary | 1 | Reuters | ||
08.11. | TELA Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
TELA BIO Aktie jetzt für 0€ handeln | |||||
07.11. | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
01.11. | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 53 | GlobeNewswire (Europe) | MALVERN, Pa., Nov. 01, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
25.10. | Insider Buying: TELA Bio, Inc. (NASDAQ:TELA) Insider Acquires 6,666 Shares of Stock | 1 | MarketBeat | ||
24.10. | Vertriebsleiter von Tela Bio, Gregory Firestone, erwirbt Aktien im Wert von 14.998 US-Dollar | 1 | Investing.com Deutsch | ||
24.10. | TELA Bio COO und CFO Roberto Cuca erwirbt Aktien im Wert von 144.999 US-Dollar | 2 | Investing.com Deutsch | ||
24.10. | TELA Bio's SWOT analysis: innovative medtech firm faces growth hurdles | 1 | Investing.com | ||
23.10. | Piper Sandler hält an Overweight-Bewertung für TELA Bio-Aktien fest | 1 | Investing.com Deutsch | ||
23.10. | Piper Sandler maintains Overweight rating on TELA Bio shares | 2 | Investing.com | ||
23.10. | TELA Bio, Inc.: TELA Bio Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants | 3 | GlobeNewswire (USA) | ||
22.10. | TELA Bio announces public offering of stock and warrants | 3 | Investing.com | ||
22.10. | TELA Bio announces public offering of common stock, pre-funded warrants | 1 | Seeking Alpha | ||
22.10. | TELA Bio, Inc.: TELA Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
22.10. | TELA Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
10.10. | TELA Bio stock plunges to 52-week low at $2.31 amid market challenges | 1 | Investing.com | ||
10.10. | TELA Bio-Aktie stürzt auf 52-Wochen-Tief von 2,31 US-Dollar | - | Investing.com Deutsch | ||
04.10. | Demystifying TELA Bio: Insights From 6 Analyst Reviews | 1 | Benzinga.com | ||
24.09. | TELA Bio-Aktie stürzt auf 52-Wochen-Tief von 2,4 US-Dollar | 1 | Investing.com Deutsch | ||
24.09. | TELA Bio stock plunges to 52-week low at $2.4 amid market challenges | 1 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EPIGENOMICS | 0,900 | -21,74 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,384 | +3,78 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
GINKGO BIOWORKS | 6,100 | +0,83 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
BEAM THERAPEUTICS | 24,480 | 0,00 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
ONCOLYTICS BIOTECH | 0,950 | +0,53 % | Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2024 Earnings Call Transcript | ||
ARCTURUS THERAPEUTICS | 16,190 | 0,00 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
ASSERTIO | 0,950 | 0,00 % | Assertio Holdings-Direktorin Heather Mason kauft Aktien im Wert von 60.000 US-Dollar | ||
SIGA TECHNOLOGIES | 6,250 | 0,00 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
ADMA BIOLOGICS | 21,370 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
VIR BIOTECHNOLOGY | 6,740 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
VERVE THERAPEUTICS | 4,550 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
ARVINAS | 22,690 | 0,00 % | Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode | ||
TRAVERE THERAPEUTICS | 16,500 | -2,94 % | Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level | ||
BIO-PATH | 0,790 | 0,00 % | Bio-Path Holdings, Inc.: Bio-Path Holdings Reports Third Quarter 2024 Financial Results | Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology... ► Artikel lesen |